Dependence, Melanosis Coli and Long-Term Risk

This is the article that justifies the whole set. Senna works — that part is settled. What is not settled, and what gets written about badly in both directions, is what happens to people who take it for months or years.

You will find confident claims on both sides. One camp says stimulant laxatives destroy the nerves of the colon and create a permanent, drug-dependent bowel. The other says that is a myth from the 1940s and senna is harmless indefinitely. Neither of those is what the evidence supports. There is one long-term risk that is real, common and occasionally lethal — electrolyte depletion, especially potassium. There is one long-term finding that looks alarming and is genuinely benign — melanosis coli. And there is one question that has been argued for eighty years without resolution — whether chronic use damages the colon structurally.

This page treats each of those separately, and says plainly which is which.

Table of Contents

  1. Electrolytes: The Risk That Actually Hurts People
  2. Digoxin, Diuretics and the Interactions That Matter
  3. The Loop: Low Potassium Makes Constipation Worse
  4. Melanosis Coli: What It Is
  5. Melanosis Coli and Cancer: Studied, With Mixed Results
  6. The Cathartic Colon Debate
  7. How Senna Affects Enteric Nerves: What the Animal Data Says
  8. Tolerance and “Dependence”: What Is Actually Happening
  9. Carcinogenicity: The Rodent Studies and the Human Data
  10. Rare but Real: Liver Injury, Clubbing and Other Case Reports
  11. If You Have Been Using Senna Long-Term
  12. Common Claims and the Accurate Versions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Electrolytes: The Risk That Actually Hurts People

If you take one thing from this page, take this: the documented, recurrent, sometimes fatal harm from chronic senna use is electrolyte depletion — above all hypokalaemia, meaning low blood potassium. Not colon damage. Not cancer. Potassium.

The mechanism is straightforward and follows directly from how senna works. Rhein anthrone makes the colon secrete water and electrolytes into the lumen instead of reabsorbing them. A normal colon reclaims most of the potassium presented to it; a colon in secretory overdrive does not, and the potassium leaves in the stool. One dose loses a little. A dose every night for months loses a lot.

What low potassium does:

Alongside potassium, chronic use depletes sodium, magnesium and total body water, and shifts the body’s acid balance. Winston’s review of the clinical biochemistry of anorexia nervosa reports acidosis in people misusing laxatives, and metabolic alkalosis in those who vomit or misuse diuretics; Copeland’s 1994 patient needed haemodialysis for worsening acidosis (pH 7.05). Roerig and colleagues’ 2010 review of laxative abuse describes secondary hyperaldosteronism — the body’s hormonal response to chronic volume loss, which drives potassium down further: the renin-aldosterone system becomes activated by the fluid loss, which leads to swelling and acute weight gain when the laxative is stopped.

None of this is exotic. It is the single most common reason someone using senna long-term ends up in hospital.

Digoxin, Diuretics and the Interactions That Matter

Potassium loss is not equally dangerous for everyone. Three medication categories turn a moderate risk into a serious one.

DrugWhy senna mattersWhat clinicians do
DigoxinDigoxin and potassium compete for the same pump in heart muscle. When potassium falls, digoxin binds more, and a previously safe dose becomes toxic — nausea, visual disturbance, dangerous arrhythmias.Treated as a combination requiring medical oversight and potassium monitoring.
Loop and thiazide diuretics (furosemide, bumetanide, bendroflumethiazide, hydrochlorothiazide, indapamide)These lower potassium in their own right. Senna adds a second, independent loss through a different route.Check potassium when both are in use.
Corticosteroids (prednisolone, dexamethasone)Mineralocorticoid activity promotes renal potassium loss. Additive with senna.Same concern: added potassium loss.
WarfarinDiarrhoea alters vitamin K absorption and gut flora; international normalized ratio (INR) control can drift.Monitor the international normalized ratio more closely when senna use goes beyond a day or two.
Any narrow-therapeutic-index oral drug (levothyroxine, antiepileptics, immunosuppressants)Faster transit can reduce absorption.Separate dosing times and watch for reduced effect.

Two combinations deserve extra emphasis because they recur in case reports: senna plus a diuretic in an older adult, and senna plus digoxin. For people in either group, the potassium question is not theoretical, and a blood test is cheap.

See our Potassium page for what normal and low levels mean and which foods restore them.

The Loop: Low Potassium Makes Constipation Worse

Here is the cruel part: a plausible mechanism for some of what people call “laxative dependence.” No study cited on this page measures how often it is the cause.

Potassium is required for normal smooth-muscle contraction. The colon is smooth muscle. When potassium falls far enough, colonic motility slows — in severe hypokalaemia, to the point of frank ileus, a bowel that has stopped moving altogether.

So the sequence for someone using senna nightly looks like this:

  1. Senna nightly → steady potassium loss in stool.
  2. Potassium falls → colon contracts more weakly.
  3. Constipation gets worse → the usual dose seems to have stopped working.
  4. Dose increases → more potassium loss.
  5. Repeat.

From the inside this feels exactly like the bowel becoming dependent on the drug. Where low potassium is the cause, it is a correctable electrolyte problem. That distinction matters enormously, because the two explanations lead to opposite actions: “my colon is damaged” leads to resignation, while “my potassium is low” leads to a blood test and a fix.

A potassium blood test is how this explanation is confirmed or ruled out when a laxative appears to have stopped working after prolonged use. The 2005 expert review on this page offers a different reading of dependence: “A proportion of patients with chronic constipation is dependent of laxatives to achieve satisfactory bowel function, but this is not the result of prior laxative intake. Tolerance to stimulant laxatives is uncommon.”

Melanosis Coli: What It Is

Melanosis coli is a brown-to-black discolouration of the colonic lining, usually noticed incidentally during colonoscopy. Reports describe it as looking like tiger skin, or crocodile skin, or as if the bowel had been stained with tea. It is the classic marker of anthraquinone laxative use, though not proof of it (see below), and it appears after roughly four to twelve months of regular use.

The pathology is well worked out. Walker, Bennett and Axelsen showed in 1988 that the anthraquinone danthron induces apoptosis — programmed cell death — in surface colonic epithelial cells of guinea pigs, and that biopsies from patients suggested the same process. The dead cells are engulfed by macrophages in the lamina propria just beneath the surface, and the residual pigment accumulates in those macrophages as a lipofuscin-like material. That pigment, not melanin despite the name, is what you see. Walker, Smith and Smithers’ 1993 electron-microscopy study of human biopsies and Byers and colleagues’ 1997 histopathology work confirmed the association with epithelial apoptosis.

Key facts:

When a colonoscopy report mentions melanosis coli, the pigment itself is not the concern; the useful question it raises is how long senna or a similar laxative has been in use.

Melanosis Coli and Cancer: Studied, With Mixed Results

For a period in the 1980s and 1990s there was genuine concern that anthranoid laxatives might raise colorectal cancer risk. The concern had a rational basis: anthraquinones are structurally related to compounds with genotoxic potential, some laboratory assays were positive, and earlier studies raised a signal. Nusko and colleagues’ 1993 retrospective study of 2,277 patients found no significant increase in colorectal cancer with laxatives or melanosis coli, but did find an association with adenomas (relative risk 1.72 for laxative users, 2.19 for melanosis coli). Siegers and colleagues (1993) reported a prospective series of 1,095 patients with pseudomelanosis coli in 18.6% of those with colorectal cancer against 6.9% of those with a normal endoscopy, and calculated a relative risk of 3.04 (1.18–4.90). Van Gorkom and colleagues reviewed the whole question in 1999, noted that melanosis had recently been associated with an increased risk of colorectal carcinoma, and concluded: “Although the short-term use of these substances is generally safe, long-term use cannot be recommended.”

The question was then tested again. Nusko and colleagues ran a prospective case-control study, published in Gut in 2000, and found that anthranoid laxative use was not a risk factor for colorectal neoplasia. It was a single-centre study of 202 people with colorectal cancer, 114 with adenomas and 238 controls, with laxative use taken from interviews; the adjusted odds ratio for cancer was 0.93 (0.5–1.7). The same group that had raised the concern with retrospective data tested it prospectively and reported the null result.

Why earlier studies found an association is not settled. Nusko’s 1993 paper offers one explanation: “polyps can be diagnosed in the dark mucosa of melanosis coli patients more easily.” Another proposed explanation is confounding by indication: people with chronic constipation take more laxatives and undergo more colonoscopies, so anything detectable by colonoscopy is found more often in laxative users. Either would be detection bias, not causation, though neither was measured in those studies.

Morales and colleagues addressed the senna-specific version of the question directly in a 2009 review in Journal of Toxicology, examining cathartic colon, genotoxicity and carcinogenicity together, and did not find support for a carcinogenic effect at therapeutic doses.

The current position is that senna at therapeutic doses has not been shown to increase colorectal cancer risk in humans, and melanosis coli is not a precancerous condition. The question is not fully closed.

A large prospective study complicates the picture. Among 75,214 adults followed to 2008 (Citronberg and colleagues, 2014), people who used non-fiber laxatives 1–4 times a year had a higher colorectal cancer rate than those using them less than once a year (hazard ratio 1.49, 95% confidence interval 1.04–2.14); for 5 or more uses a year the figure was 1.43 (0.82–2.28). People who often used fiber laxatives had a lower rate (0.44, 0.21–0.95). Non-fiber laxatives were counted as one group, not senna alone, and the authors state that further studies are needed.

The Cathartic Colon Debate

“Cathartic colon” describes a radiological appearance reported from the 1940s onwards in long-term laxative users: a dilated, featureless colon with loss of the normal haustral markings, sometimes with a gaping ileocaecal valve and strictured segments. The interpretation attached to it was that chronic stimulant laxatives had destroyed the colon’s neuromuscular apparatus, producing an irreversibly inert bowel.

That interpretation became textbook doctrine and is the reason for every “do not use for more than a week” label in existence. It has been under sustained challenge for thirty years. Here is the honest state of the argument.

The case that cathartic colon is real

The case against

Where that leaves it

The strong claim — that ordinary therapeutic senna use permanently damages the colon and creates true dependence — is not supported by good evidence, and the weight of expert opinion over the last three decades has moved against it. But the definitive study has never been run: nobody has randomised people to years of senna versus placebo and imaged their colons afterwards, and nobody will. So “not supported” is not the same as “disproven,” and the duration limits stand as a precaution.

Current guidelines differ in emphasis. The 2023 American Gastroenterological Association and American College of Gastroenterology guideline gives senna a conditional recommendation for chronic constipation, with strong recommendations for polyethylene glycol and sodium picosulfate. The 2023 Japanese guideline places osmotic laxatives first among oral drugs and says stimulant laxatives are “exclusively designated for as-needed use.”

What that means for a reader: the case against long-term senna rests on the electrolyte risk, which is real. Three weeks of use has not been shown to ruin the bowel, and no good evidence supports that fear.

How Senna Affects Enteric Nerves: What the Animal Data Says

The neuronal-damage hypothesis has been tested in animals, and the results do not line up neatly.

Two honest caveats apply to all of it. First, these papers do not establish how an animal dose maps onto human use. Second, ultrastructural change is not the same as functional loss — showing an altered appearance under an electron microscope does not demonstrate that the colon works worse.

The fair summary: the best experiment designed to detect senna-induced neuronal death did not find it, a synthetic anthraquinone damaged gut nerves in mice while sennosides did not, and none of this establishes the classic cathartic-colon picture in humans at ordinary doses.

Tolerance and “Dependence”: What Is Actually Happening

People who use senna nightly for months often report that they need more of it, and that stopping produces several days of no bowel movement at all. Both experiences are real. Neither requires nerve damage to explain.

  1. Hypokalaemia slowing the colon — the loop described above. This is a plausible mechanism and not a measured one; where it is the cause, it is correctable.
  2. Post-laxative emptiness. A colon emptied more thoroughly than normal genuinely has less to deliver. It takes two to four days of eating for the colon to refill to the point where a normal bowel movement is possible. That gap is routinely misread as “my bowel has stopped working without the drug.” It has not; it is empty.
  3. The underlying condition was never treated. Whatever caused the constipation — medication, hypothyroidism, low fibre, pelvic-floor dyssynergia, immobility — is still there and still progressing. The laxative was masking it.
  4. Psychological expectation. Regular users often develop an expectation of a daily bowel movement and anxiety when it does not occur, which itself affects gut function through the brain-gut axis. This is not imaginary; it is a documented feature of laxative-dependent patients.
  5. Genuine pharmacological tolerance — a reduced response to the same dose at the receptor or enzyme level — is the explanation with the least supporting evidence in humans, despite being the one most often assumed.

Practical consequence: people stopping long-term senna describe a few uncomfortable days. These are not proof of permanent damage; the 2005 expert review found “no indication for the occurrence of ‘rebound constipation’ after stopping laxative intake.” A potassium test and a search for the underlying cause are the alternatives to restarting at a higher dose.

Carcinogenicity: The Rodent Studies and the Human Data

Senna has been through formal toxicology, which is more than most botanicals can say.

Important framing: this body of work concerns senna as a standardised preparation at defined doses. It does not license unlimited consumption, and it does not extend to the undisclosed anthranoid loads in unregulated “cleanse” blends that stack senna with cascara and aloe. A separate note: some purified single anthraquinones, such as emodin and aloe-emodin, have shown activity in laboratory genotoxicity assays. The laboratory positives were not limited to isolated compounds: Mengs 1999 notes that the senna extract itself “gave positive responses in vitro in the Ames test and in the CHO assay,” a result not confirmed in the live mouse test, and Morales 2009 classes the genotoxic activity of sennosides as weak where it was significant. These are cell-system findings, not findings about senna tablets in people.

Rare but Real: Liver Injury, Clubbing and Other Case Reports

A handful of unusual harms appear in the case literature. Most involve substantial overuse; the skin injury series involved young children who swallowed senna laxatives by accident.

If You Have Been Using Senna Long-Term

What reviews and clinicians describe for long-term users:

  1. A potassium test. A basic metabolic panel covers potassium, sodium, bicarbonate and kidney function; magnesium is usually a separate test. This is the single highest-value step, and it is a routine, cheap blood test.
  2. A medication review — specifically for digoxin, diuretics and corticosteroids.
  3. A search for the cause of the constipation. Thyroid function, medication review, coeliac screen, and consideration of pelvic-floor dysfunction, which is common, treatable and completely unresponsive to laxatives.
  4. Stopping: accounts differ. Roerig and colleagues’ 2010 review says “the first intervention would be to stop the stimulant laxatives and replace them with fibre/osmotic supplements.” Others describe tapering from high doses, bridged with an osmotic laxative such as polyethylene glycol or lactulose, which do not carry the same electrolyte-loss profile, while fibre and fluid are built up. Osmotic laxatives have an open question of their own: in 502,229 UK Biobank adults, regular laxative use was linked to more dementia (hazard ratio 1.51, 1.30–1.75), and among people using one type only, the significant link was with osmotic laxatives (1.64, 1.20–2.24). This is an association, not proof of cause.
  5. Two to four days without a bowel movement are commonly described after stopping. That is an empty colon refilling, not a damaged one.
  6. The boring foundation: gradual fibre with adequate fluid, daily movement, and unhurried toilet time after breakfast when the gastrocolic reflex is strongest. The 2005 expert review adds that some patients are helped by fibre but “many patients with more severe constipation get worse symptoms when increasing dietary fiber intake,” and that “there is no evidence that constipation can successfully be treated by increasing fluid intake unless there is evidence of dehydration.”
  7. When laxative use is tied to weight or body image, the plan changes entirely, and this is common — see Senna in Weight-Loss and Detox Teas.

Common Claims and the Accurate Versions

Claim you will hearAccurate version
“Senna makes your bowel lazy and dependent.”Not supported by good evidence. Proposed explanations for apparent dependence are low potassium, an empty colon, or an untreated underlying cause.
“Senna causes colon cancer.”Not shown for senna. Nusko’s 2000 case-control study found no link; a 2014 cohort of all non-fiber laxatives found a higher rate without separating senna.
“Melanosis coli means damage.”Benign, symptomless, reversible within 6–12 months of stopping.
“Cathartic colon is settled science.”Genuinely contested. Described in an era of harsher agents; largely absent from modern practice; not disproven either.
“Senna is natural, so long-term use is fine.”The potassium risk is real, cumulative and occasionally fatal. This is the claim that actually gets people hurt.
“One week is an arbitrary limit.”It is precautionary rather than proven. The US drug label reads “Do not use laxative products for longer than 1 week unless directed by a doctor”; its separate 2-week item concerns a sudden change in bowel habits.

Key Research Papers

Every identifier below was verified live against NCBI E-utilities — author, title, journal and year all had to match.

The cathartic-colon debate

  1. Whorwell P, Lange R, Scarpignato C. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therapeutic Advances in Gastroenterology. 2024;17:17562848241249664 — PubMed PMID: 38887508 — The most recent critical appraisal; found the damage evidence weak.
  2. Müller-Lissner S. What has happened to the cathartic colon? Gut. 1996;39(3):486–488 — PubMed PMID: 8949659 — Notes the syndrome’s disappearance from modern practice.
  3. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. The American Journal of Gastroenterology. 2005;100(1):232–242. — PubMed PMID: 15654804
  4. Wald A. Is chronic use of stimulant laxatives harmful to the colon? Journal of Clinical Gastroenterology. 2003;36(5):386–389. — PubMed PMID: 12702977
  5. Joo JS, Ehrenpreis ED, Gonzalez L, et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. Journal of Clinical Gastroenterology. 1998;26(4):283–286 — PubMed PMID: 9649012 — The other side of the argument — argued the entity is real.
  6. Morales MA, Hernández D, Bustamante S, Bachiller I, Rojas A. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity? Journal of Toxicology. 2009;2009:287247. — PubMed PMID: 20107583

Enteric nerve and mucosal effects

  1. Kiernan JA, Heinicke EA. Sennosides do not kill myenteric neurons in the colon of the rat or mouse. Neuroscience. 1989;30(3):837–842 — PubMed PMID: 2570374 — Animal study; negative for the neuronal-damage hypothesis.
  2. Riemann JF, Schmidt H, Zimmermann W. The fine structure of colonic submucosal nerves in patients with chronic laxative abuse. Scandinavian Journal of Gastroenterology. 1980;15(6):761–768 — PubMed PMID: 7209384 — Human electron microscopy; uncontrolled for underlying disease.
  3. Dufour P, Gendre P. Ultrastructure of mouse intestinal mucosa and changes observed after long term anthraquinone administration. Gut. 1984;25(12):1358–1363 — PubMed PMID: 6510768 — Animal study.
  4. Dufour P, Gendre P. Long-term mucosal alterations by sennosides and related compounds. Pharmacology. 1988;36(Suppl 1):194–202 — PubMed PMID: 3368519 — Animal study.

Melanosis coli

  1. Walker NI, Bennett RE, Axelsen RA. Melanosis coli: a consequence of anthraquinone-induced apoptosis of colonic epithelial cells. The American Journal of Pathology. 1988;131(3):465–476 — PubMed PMID: 3381879 — The mechanistic paper.
  2. Byers RJ, Marsh P, Parkinson D, Haboubi NY. Melanosis coli is associated with an increase in colonic epithelial apoptosis and not with laxative use. Histopathology. 1997;30(2):160–164 — PubMed PMID: 9067741 — Complicates the simple story — apoptosis, not laxative use per se, tracked with pigmentation.
  3. Freeman HJ. “Melanosis” in the small and large intestine. World Journal of Gastroenterology. 2008;14(27):4296–4299. — PubMed PMID: 18666316
  4. Yang N, Ruan M, Jin S. Melanosis coli: a comprehensive review. Gastroenterología y Hepatología. 2020;43(5):266–272. — PubMed PMID: 32094046
  5. Walker NI, Smith MM, Smithers BM. Ultrastructure of human melanosis coli with reference to its pathogenesis. Pathology. 1993;25(2):120–123 — PubMed PMID: 8367190

Cancer risk and toxicology

  1. Nusko G, Schneider B, Schneider I, Wittekind C, Hahn EG. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut. 2000;46(5):651–655 — PubMed PMID: 10764708 — A prospective case-control human study — negative.
  2. van Gorkom BA, de Vries EG, Karrenbeld A, Kleibeuker JH. Review article: anthranoid laxatives and their potential carcinogenic effects. Alimentary Pharmacology & Therapeutics. 1999;13(4):443–452 — PubMed PMID: 10215727 — The review that framed the concern before it was tested.
  3. Mitchell JM, Mengs U, McPherson S, et al. An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat. Archives of Toxicology. 2006;80(1):34–44 — PubMed PMID: 16205914 — Animal study.
  4. Mengs U, Mitchell J, McPherson S, Gregson R, Tigner J. A 13-week oral toxicity study of senna in the rat with an 8-week recovery period. Archives of Toxicology. 2004;78(5):269–275 — PubMed PMID: 14997282 — Animal study with a reversibility arm.
  5. Mengs U, Grimminger W, Krumbiegel G, Schüler D, Silber W, Völkner W. No clastogenic activity of a senna extract in the mouse micronucleus assay. Mutation Research. 1999;444(2):421–426 — PubMed PMID: 10521682 — Animal genotoxicity — negative.
  6. Citronberg J, Kantor ED, Potter JD, White E. A prospective study of the effect of bowel movement frequency, constipation, and laxative use on colorectal cancer risk. The American Journal of Gastroenterology. 2014;109(10):1640–1649 — PubMed PMID: 25223576
  7. Siegers CP, von Hertzberg-Lottin E, Otte M, Schneider B. Anthranoid laxative abuse — a risk for colorectal cancer? Gut. 1993;34(8):1099–1101 — PubMed PMID: 8174962
  8. Nusko G, Schneider B, Müller G, Kusche J, Hahn EG. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma. Pharmacology. 1993;47(Suppl 1):234–241 — PubMed PMID: 8234435

Electrolytes, misuse and rare harms

  1. Roerig JL, Steffen KJ, Mitchell JE, Zunker C. Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010;70(12):1487–1503. — PubMed PMID: 20687617
  2. Winston AP. The clinical biochemistry of anorexia nervosa. Annals of Clinical Biochemistry. 2012;49(Pt 2):132–143 — PubMed PMID: 22349551 — Describes the laxative-misuse laboratory picture.
  3. Copeland PM. Renal failure associated with laxative abuse. Psychotherapy and Psychosomatics. 1994;62(3–4):200–202. — PubMed PMID: 7531354
  4. Bytzer P, Stokholm M, Andersen I, Klitgaard NA, Schaffalitzky de Muckadell OB. Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: a cost benefit analysis of a screening procedure. Gut. 1989;30(10):1379–1384. — PubMed PMID: 2511089
  5. Vanderperren B, Rizzo M, Angenot L, Haufroid V, Jadoul M, Hantson P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. The Annals of Pharmacotherapy. 2005;39(7–8):1353–1357 — PubMed PMID: 15956233 — Case report; gross overdose.
  6. Prior J, White I. Tetany and clubbing in patient who ingested large quantities of senna. The Lancet. 1978;2(8096):947. — PubMed PMID: 81966
  7. FitzGerald O, Redmond J. Anthraquinone-induced clubbing associated with laxative abuse. Irish Journal of Medical Science. 1983;152(6):246–247. — PubMed PMID: 6874294
  8. Spiller HA, Winter ML, Weber JA, Krenzelok EP, Anderson DL, Ryan ML. Skin breakdown and blisters from senna-containing laxatives in young children. The Annals of Pharmacotherapy. 2003;37(5):636–639 — PubMed PMID: 12708936
  9. Vierhapper H, Waldhäusl. [Laxative-induced hypokalemic myopathy. A case history]. Wiener Klinische Wochenschrift. 1980;92(3):101–103 — PubMed PMID: 6930755
  10. Yang Z, Wei C, Li X, et al. Association between regular laxative use and incident dementia in UK Biobank participants. Neurology. 2023;100(16):e1702–e1711 — PubMed PMID: 36813729
  11. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086–1106 — PubMed PMID: 37211380
  12. Ihara E, Manabe N, Ohkubo H, et al. Evidence-based clinical guidelines for chronic constipation 2023. Digestion. 2025;106(1):62–89 — PubMed PMID: 39159626

PubMed Topic Searches

  1. PubMed: Cathartic colon
  2. PubMed: Melanosis coli reversibility
  3. PubMed: Laxative abuse and hypokalaemia
  4. PubMed: Hypokalaemia and digoxin toxicity
  5. PubMed: Stimulant laxative long-term safety
  6. PubMed: Anthranoid laxatives and colorectal neoplasia
  7. PubMed: Hypokalaemia and colonic motility
  8. PubMed: Laxative withdrawal management

Connections


Back to Table of Contents